Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India

Abstract

BackgroundHormone receptor status is an important prognostic and therapeutic tool in breast cancer. The objectives of our study were to create a database of breast cancer patients in Central Kerala between January 2010 and December 2012 and analyze the proportions of estrogen receptor and progesterone receptor positivity in premenopausal and postmenopausal women with breast cancer.MethodsEstrogen and progesterone receptor status were evaluated by immunohistochemistry. The chi-square test was used for statistical analysis.ResultsThe median age at diagnosis was 50 years while the mean age was 51.92 (SD = 11.78). 56.1% of premenopausal and 47.4% of postmenopausal patients were found to be ER positive, while PR positivity was 47.7% and 34.7% respectively in the premenopausal and postmenopausal age groups.ConclusionsThe proportions of ER and PRnegative tumors were found to be lower than reported in earlier studies on Indian populations. Contrary to expectations, the proportions of ER and PRpositivity were found to be higher in the premenopausal age group.

Hormone Receptor Status of Breast Cancer in Northern Region of India- A Study

“…[23] The average ER positivity for white women in the US is 77%. PR positivity from our study in female breast cancer cases is 45% which is close to percentage of ER value and comparable to other studies reported from different parts of India with PR expression of 33.3%, [24] 41.5%, [25] and 42%. [26] Though white women in US showed 55% PR positivity.…”

“…Most other studies have found 51 -60 years as the second most common decade for breast cancer. [19] In our study, the overall ER positivity in female breast cancer cases is found to be 44.0%, which lies in the range reported by different Indian institutes, however, pretty low as compared to the reportings form western world. [20] ER negative and PR positive tumours are relatively rare cancers based on hormone receptor expression which accounts for just 1-4% [21] of all cases according to Navani et al and was found to be 5.3% [22] in the study of Vettuparambil et al Studies done in India and on Indian emigrants have found ER positivity in Indian women in the range of 34.5% to 55.1%.…”

Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India

“…[ 8 ] There is an annual rise of 0.5%–2% in the incidence across all regions of India and this rise is even more in younger females less than 45 years. [ 9 ] Most Indian studies to date have shown median ages ranging from 48-53 years. [ 7 8 9 10 11 ] In our study as well, the median age was 48 years, reinforcing the fact that breast cancer in Indian women occurs at least a decade younger than those in the West.…”

“…[ 9 ] Most Indian studies to date have shown median ages ranging from 48-53 years. [ 7 8 9 10 11 ] In our study as well, the median age was 48 years, reinforcing the fact that breast cancer in Indian women occurs at least a decade younger than those in the West. [ 12 ] Most western data show a median age around 60 years.…”

Prognostic subtyping based on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor2 expression in breast cancer cases among north Indian females

“…The prevalence of ER and PR expression has been found similar in some Indian studies but in western literature studies have found much higher prevalence as compared to the studies in India. [6][7][8][9] This difference could be because of different genetic pool and ethnic differences. We found about 9.6% of cases being triple negative for receptors in our study population.…”